الفهرس 
Introduction
Chapter 1: chronic kidney diseaseOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
Chronic kidney disease is a rapidly growing global health problem. Neurological complications of CKD may be disease related or treatment related. It affects both central and peripheral nervous systems. Uremic neuropathy is a distal, painless, progressive sensorimotor polyneuropathy caused by uremic toxins in patients with advanced chronic kidney disease. It is dying-back neuropathy or central peripheral axonopathy associated with secondary demylination. Erythropoietin is a glycoprotein produced from the kidney. It regulates erythropoiesis. It was found to have different actions in many organs as cardiovascular system, kidney, skin, reproductive system and nervous system. It was found that EPO acts as neuroprotective agent in brain after exposure to injury as ischemia, seizure or encephalomyelitis. It also has neuroprotective effect on peripheral nerves as it has anti-apoptotic effect. Our study included 24 anemic chronic renal disease patients. They were selected from internal medicine inpatient department as well as the dialysis unit of Minia University Hospital. Six patients were dropped. Clinical assessment (by DNS and ONLS), laboratory (serum creatinine, blood urea and Hb) and neurophysiological study were done before and after 3 months of treatment for all patients. Patients were divided into 2 groups (patients who received EPO and those who didn’t receive EPO) for comparing results. Also, results of patients who received EPO both diabetic and non-diabetic patients were compared.